Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18776861 | PEPTIDE-UREA DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND APPLICATION THEREOF | July 2024 | June 2025 | Allow | 11 | 2 | 1 | Yes | No |
| 18770529 | RADIOPHARMACEUTICAL COMPOSITION AND METHODS | July 2024 | February 2025 | Allow | 7 | 1 | 1 | No | No |
| 18070994 | Temporary Wrinkle Softener | November 2022 | February 2025 | Abandon | 26 | 3 | 0 | Yes | No |
| 17981502 | TOOTHPASTE CAPSULE | November 2022 | April 2024 | Abandon | 18 | 1 | 0 | No | No |
| 17944620 | Jammed Emulsion Toothpaste Compositions | September 2022 | June 2025 | Allow | 33 | 4 | 0 | No | Yes |
| 17595709 | SURFACTANT MICROBUBBLES COMPOSITIONS AND PROCESS FOR PREPARING THEREOF | November 2021 | May 2024 | Allow | 30 | 1 | 0 | No | No |
| 17612953 | METHODS AND COMPOSITIONS FOR INHIBITING GAPDH | November 2021 | August 2024 | Abandon | 33 | 1 | 0 | No | No |
| 17612123 | 3,5-BIS(PHENYL)-1H-HETEROARYL DERIVATIVES AS MEDICAMENTS | November 2021 | April 2025 | Abandon | 41 | 3 | 0 | No | No |
| 17502010 | MICROBUBBLE DISPERSION SYSTEM STABILIZED WITH POLYDOPAMINE NANOPARTICLES FOR HIGHLY-EFFICIENT INTRAVENOUS OXYGEN SUPPLY AND METHOD FOR PREPARING THE SAME | October 2021 | February 2025 | Allow | 40 | 1 | 0 | No | No |
| 17450264 | COXIB-DERIVED CONJUGATE COMPOUNDS AND METHODS OF USE THEREOF | October 2021 | May 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17488810 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | September 2021 | July 2024 | Allow | 33 | 2 | 0 | No | No |
| 17437380 | COMPOSITION FOR MEASURING MEDICATION COMPLIANCE AND METHOD THEREOF | September 2021 | February 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17310759 | COMBINATION OF AR ANTAGONISTS AND TARGETED THORIUM CONJUGATES | August 2021 | June 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17432039 | HIPK INHIBITORS AND METHODS OF USE THEREOF | August 2021 | January 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17402092 | ANALYTE-SENSITIVE PROBES AND CONTACT LENS FOR DIAGNOSIS OF OCULAR PATHOLOGIES | August 2021 | September 2024 | Abandon | 37 | 1 | 0 | No | No |
| 17310604 | Targeted Radiopharmaceutical for Tumor and Its Use in the Imaging-guided Combination Therapy of Targeted Radiotherapy and Immunotherapy | August 2021 | March 2025 | Allow | 43 | 2 | 0 | No | No |
| 17430263 | NEUROTRANSMITTER-BASED BRAIN MAPPING METHOD AND USE OF BRAIN MAP | August 2021 | December 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17428732 | TREATMENT EFFICIENCY EVALUATION | August 2021 | July 2025 | Abandon | 47 | 2 | 0 | No | No |
| 17426962 | PSMA BINDING DUAL MODE RADIOTRACER AND THERAPEUTIC | July 2021 | March 2025 | Allow | 44 | 1 | 1 | No | No |
| 17427006 | CANCER DIAGNOSTIC IMAGING AGENTS | July 2021 | May 2025 | Allow | 46 | 2 | 1 | Yes | No |
| 17387258 | Transition Metal Macrocyclics as MRI Contrast Agents for Molecular Imaging | July 2021 | June 2024 | Abandon | 34 | 2 | 0 | No | No |
| 17424973 | NON-HUMAN ANIMAL MODELS OF S�ZARY SYNDROME | July 2021 | October 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17423526 | Compound Targeting Norepinephrine Transporter | July 2021 | March 2025 | Allow | 44 | 2 | 1 | Yes | No |
| 17422211 | GRAPHENE QUANTUM DOTS-GADOLINIUM ION CHELATE AS MAGNETIC RESONANCE IMAGING CONTRAST AGENT AND PREPARATION METHOD THEREOF | July 2021 | December 2024 | Allow | 41 | 1 | 1 | Yes | No |
| 17421995 | COMPOSITION FOR TARGETING MEDULLARY THYROID CANCER | July 2021 | January 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17421239 | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 4 | July 2021 | November 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17420671 | RADIOTHERAPEUTIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | July 2021 | November 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17420666 | MOLECULAR RENAL PROBES FOR DETECTING ACUTE KIDNEY INJURY | July 2021 | January 2025 | Allow | 42 | 1 | 1 | No | No |
| 17420218 | Prediction and/or Determination Marker for Effectiveness of Treatment with Drug Containing PD-1 Signal Inhibitor | July 2021 | March 2025 | Abandon | 45 | 2 | 0 | No | No |
| 17419649 | MAGNETIC RESONANCE IMAGING DRUG CONTAINING A DEUTERATED NATURAL BRANCHED-CHAIN AMINO ACID, AND DIAGNOSTIC METHOD USING SAID DRUG | June 2021 | June 2025 | Abandon | 47 | 2 | 1 | No | No |
| 17419381 | Methods for Treating Cancer Using Combinations of PARP Inhibitors and Antibody Radioconjugates | June 2021 | February 2025 | Abandon | 43 | 2 | 0 | No | No |
| 17312949 | RADIOACTIVE I-LABELED LAROTRECTINIB COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF | June 2021 | July 2024 | Allow | 37 | 0 | 1 | Yes | No |
| 17327551 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING | May 2021 | December 2024 | Allow | 43 | 2 | 0 | No | No |
| 17294187 | BENZAZEPIN-L,7-DIOL-DERIVED RADIOLABELED LIGANDS WITH HIGH IN VIVO NMDA SPECIFICITY | May 2021 | May 2025 | Abandon | 48 | 2 | 0 | No | No |
| 17293455 | RADIOLABELED BOMBESIN-DERIVED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | May 2021 | September 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17285775 | Phospholipid-Free Small Unilamellar Vesicles (PFSUVS) for Drug Delivery | April 2021 | May 2025 | Abandon | 49 | 3 | 0 | No | No |
| 17283761 | Hybrid Tracers for Targeted Cancer Imaging and Treatment | April 2021 | May 2025 | Allow | 50 | 3 | 0 | No | No |
| 17176123 | CEST-MRI Methods for Detection of Diseases | February 2021 | October 2024 | Abandon | 44 | 0 | 1 | No | No |
| 17267175 | BINDNG MOLECULES TO TUMOR ASSOCIATED MACROPHAGES AND METHODS OF USE | February 2021 | June 2025 | Abandon | 52 | 2 | 0 | No | Yes |
| 17052275 | BACTERIOPHAGE-BASED SERS-ACTIVE GOLD NANOHALO STRUCTURE AND MANUFACTURING METHOD THEREFOR | February 2021 | September 2024 | Abandon | 46 | 2 | 0 | No | No |
| 17266383 | Separation of Radiometals | February 2021 | July 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17057624 | A Drug For Treating Disorders Of An Organ Or Tissue Function And Diseases Accompanied By Such Disorders, And The Method For Obtaining It. | November 2020 | June 2025 | Abandon | 55 | 2 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CRAIG, KAILA ANGELIQUE.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 50.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner CRAIG, KAILA ANGELIQUE works in Art Unit 1618 and has examined 40 patent applications in our dataset. With an allowance rate of 32.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.
Examiner CRAIG, KAILA ANGELIQUE's allowance rate of 32.5% places them in the 2% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by CRAIG, KAILA ANGELIQUE receive 1.40 office actions before reaching final disposition. This places the examiner in the 30% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by CRAIG, KAILA ANGELIQUE is 41 months. This places the examiner in the 5% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +40.2% benefit to allowance rate for applications examined by CRAIG, KAILA ANGELIQUE. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 27.8% of applications are subsequently allowed. This success rate is in the 39% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 22.2% of cases where such amendments are filed. This entry rate is in the 20% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 84% percentile among all examiners. Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 75.0% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.